In vitro and in vivo multidrug resistance reversal activity by a Betti-base derivative of tylosin

N. Gyémánt, H. Engi, Z. Schelz, I. Szatmári, D. Tóth, F. Fülöp, J. Molnár, P. A.M. De Witte

Research output: Contribution to journalArticle

29 Citations (Scopus)


Background:The multidrug resistance (MDR) proteins are present in a majority of human tumours. Their activity is important to understand the chemotherapeutic failure. A search for MDR-reversing compounds was conducted among various Betti-base derivatives of tylosin.Methods:Here, we evaluate the in vitro and in vivo P-glycoprotein (P-gp)-modulating activity of the most promising compound N-tylosil-1-α-amino-(3-bromophenyl)-methyl-2-naphthol (TBN) using human MDR1 gene-transfected and parental L5178 mouse lymphoma cell lines.Results:In vitro experiments showed that TBN dramatically increased the P-gp-mediated cellular uptake of the fluorescent substrate rhodamine 123. Similarly, TBN was found to act as a very potent enhancer of the cytotoxicity of doxorubicin on the resistant cell line. We also provide in vivo evidence using DBA2 mice in support for an increased tumoural accumulation of doxorubicin, without affecting its tissue distribution, resulting in an enhanced antitumoural effect.Conclusion:Our results suggest that TBN is a potent modulator of the P-gp membrane pump and that the compound could be of clinical relevance to improve the efficacy of chemotherapy in MDR cancers.

Original languageEnglish
Pages (from-to)178-185
Number of pages8
JournalBritish journal of cancer
Issue number2
Publication statusPublished - Jul 13 2010

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'In vitro and in vivo multidrug resistance reversal activity by a Betti-base derivative of tylosin'. Together they form a unique fingerprint.

  • Cite this